These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 15073866

  • 1. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
    Wagner S, Erdlenbruch B, Längler A, Gnekow A, Kühl J, Albani M, Völpel S, Bucsky P, Emser A, Peters O, Wolff JE.
    Cancer; 2004 Apr 15; 100(8):1750-7. PubMed ID: 15073866
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase II evaluation of topotecan for pediatric central nervous system tumors.
    Blaney SM, Phillips PC, Packer RJ, Heideman RL, Berg SL, Adamson PC, Allen JC, Sallan SE, Jakacki RI, Lange BJ, Reaman GH, Horowitz ME, Poplack DG, Balis FM.
    Cancer; 1996 Aug 01; 78(3):527-31. PubMed ID: 8697400
    [Abstract] [Full Text] [Related]

  • 5. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1999 Jan 01; 5(1):69-75. PubMed ID: 9918204
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
    Frangoul H, Ames MM, Mosher RB, Reid JM, Krailo MD, Seibel NL, Shaw DW, Steinherz PG, Whitlock JA, Holcenberg JS.
    Clin Cancer Res; 1999 Dec 01; 5(12):3956-62. PubMed ID: 10632325
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, Adamson PC, Krailo MD, Bleyer WA, Poplack DG, Balis FM.
    Clin Cancer Res; 1998 Feb 01; 4(2):357-60. PubMed ID: 9516923
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases.
    Kocher M, Eich HT, Semrau R, Güner SA, Müller RP.
    Strahlenther Onkol; 2005 Jan 01; 181(1):20-5. PubMed ID: 15660189
    [Abstract] [Full Text] [Related]

  • 15. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA, Al Omari A, Murry DJ, Case D.
    Lung Cancer; 2006 Dec 01; 54(3):379-85. PubMed ID: 17049403
    [Abstract] [Full Text] [Related]

  • 16. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
    O'Malley DM, Azodi M, Makkenchery A, Tangir J, McAlpine J, Kelly M, Schwartz P, Rutherford T.
    Gynecol Oncol; 2005 Aug 01; 98(2):242-8. PubMed ID: 15992916
    [Abstract] [Full Text] [Related]

  • 17. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
    Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6080-5. PubMed ID: 15447993
    [Abstract] [Full Text] [Related]

  • 18. A phase I study of periocular topotecan in children with intraocular retinoblastoma.
    Chantada GL, Fandino AC, Carcaboso AM, Lagomarsino E, de Davila MT, Guitter MR, Rose AB, Manzitti J, Bramuglia GF, Abramson DH.
    Invest Ophthalmol Vis Sci; 2009 Apr 15; 50(4):1492-6. PubMed ID: 18978345
    [Abstract] [Full Text] [Related]

  • 19. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH, McCune JS, Lindley C, Faucette S, Shord S, Donahue A, Socinski MA, Stewart CF, Zamboni WC, Kirstein MN, Moore D.
    Cancer Invest; 2005 Apr 15; 23(6):511-9. PubMed ID: 16203659
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.